Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...

A new treatment is presented that eliminates the root cause of the disease and restores ocular surface health.

Apellis Pharmaceuticals recently announced post hoc analysis data of the GALE extension study. This new data is the result of ...

Paul Badawi, Founder and CEO of Sight Sciences and Leon Herndon, MD, Duke University Eye Center, Durham, NC, commented on the ...

Inder Paul Singh, a glaucoma anterior segment surgeon from southeastern Wisconsin, presented his clinical experience and a ...

The timeline for the proposed Alcon acquisition of STAAR Surgical has once again been extended as STAAR announced amendments ...

OCT has transformed retinal practice, enhancing diagnostic accuracy and treatment efficiency while reducing reliance on ...

Donaldson introduces the panel and outlines the series’ focus on improving dry eye management through tear function ...

At AAO 2025, David Eichenbaum, Director of Research and partner at Retina Vitreous Associates of Florida, and collaborative ...